Truist Financial Corp Sells 12,060 Shares of Hologic, Inc. (NASDAQ:HOLX)

Truist Financial Corp lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 132,432 shares of the medical equipment provider's stock after selling 12,060 shares during the period. Truist Financial Corp owned 0.06% of Hologic worth $9,462,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Hologic during the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC bought a new stake in Hologic during the third quarter worth approximately $29,000. NBC Securities Inc. bought a new stake in Hologic during the third quarter worth approximately $33,000. Deseret Mutual Benefit Administrators raised its holdings in Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 155 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its holdings in Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 227 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Up 0.8 %

NASDAQ:HOLX traded up $0.63 during trading hours on Friday, hitting $76.54. 2,069,424 shares of the stock traded hands, compared to its average volume of 1,754,576. The firm has a 50 day moving average price of $76.12 and a 200 day moving average price of $72.97. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $86.74. The firm has a market cap of $17.97 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 2.58 and a beta of 1.01.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the business earned $1.06 EPS. The company's revenue was down .8% on a year-over-year basis. Equities research analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HOLX shares. Needham & Company LLC reissued a "buy" rating and set a $90.00 target price on shares of Hologic in a report on Friday. Raymond James boosted their target price on Hologic from $85.00 to $88.00 and gave the stock an "outperform" rating in a report on Friday, February 2nd. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a report on Friday. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Friday, February 2nd. Finally, JPMorgan Chase & Co. upped their price target on Hologic from $85.00 to $91.00 and gave the company an "overweight" rating in a report on Friday. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Hologic has an average rating of "Moderate Buy" and a consensus price target of $84.56.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares of the company's stock, valued at approximately $119,802.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company's stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Company insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.